Epilogue
Roman
Laboratory lights cast clinical shadows across my specimen cases, each one meticulously labeled and cataloged. The silence feels almost reverent—this is my temple of science where biology itself bends to human will.
I observe the chaos theory equations Mona left scrawled across whiteboards. Clever girl. Even in her rebellion, her brilliance shines through—a Sterling trait, however much she might deny it.
“Report,” I say without turning, sensing Alexander’s presence at the doorway. My son’s footsteps carry the slight asymmetry he’s had since childhood—since Mona’s little accident.
“We disrupted the pack structure,” Alexander states, voice carefully modulated to hide disappointment. “But failed to recover the primary assets.”
“Both of them?” I finally turn, studying the bruises darkening his jaw and the lingering unsteadiness in his posture. “Interesting.”
“Cayenne has... evolved beyond our projections.” Something flickers in his eyes—respect, perhaps. Or resentment.
I allow myself a small smile. “Of course she has. She’s a Sterling.”
I move toward the central display—genetic sequencing data scrolling across multiple screens. Under bright lights, vials of iridescent liquid gleam like captured stars, embodiments of years of painstaking research.
“The revised formula is performing as expected?” I inquire, already knowing the answer.
“Better than expected,” Alexander confirms, straightening his posture despite the obvious pain. “The London trial subjects are already showing designation shifts. No fatalities.”
“And the Seattle cohort?”
“Transformation complete in seventy-six percent of subjects. The remaining twenty-four percent show partial response but require secondary exposure.”
I nod, satisfaction warming my chest. Fourteen years of research, of trial and error, of adapting to Mona’s clever sabotage. And now, finally, success.
“Whitmore was worth every penny,” I observe.
“His modifications to the viral vector were... inspired,” Alexander agrees. “Though without your initial research, even he couldn’t have achieved designation manipulation.”
I move to a specialized containment unit, where a single vial gleams brighter than the others—golden rather than the standard iridescent blue. “And this? The Cayenne protocol?”
Alexander shifts uncomfortably. “As requested. The specialized formula targeting beta-plus mutations.”
“Designation targeting at the genomic level,” I muse, lifting the vial to examine it more closely. “Not just manipulation but evolutionary acceleration. No longer blunt force trauma to biology, but precision surgery.”
“It’s untested,” Alexander cautions. “We have no way of knowing how it will interact with her already altered genetics.”
“A happy accident,” I say with genuine pleasure. “When I designed the original virus, I never anticipated a subject might adapt rather than transform. Cayenne’s unique response has opened entirely new research avenues—the core of Project Genesis itself.”
I place the vial back in its cradle with reverent care. “One test subject hardly constitutes statistical significance. We need the others.”
“The beta. Finn.” Alexander’s voice carries a note of professional interest. “His symptoms suggest similar adaptive potential, though his resistance patterns differ from Cayenne’s.”
“Indeed. And Mona has likely administered her makeshift vaccine, which only furthers our research goals.” I turn to the wall of surveillance feeds, each tracking different members of the fractured pack. “She thinks she’s playing against me, but she’s simply expanding my dataset.”
“What about the omega? His heat symptoms were advancing rapidly during extraction.”
My eyes gleam with scientific curiosity. “An omega in full heat, bonded to enhanced betas and alphas? The pheromone interactions alone would be worth studying.”
I pull up a specialized tracking program—genetic markers identified across global surveillance networks. Red dots illuminate across the map, each representing a Sterling genetic signature.
“My daughters are clever,” I observe, watching a marker move steadily northward. “But every Sterling carries my genetic signature. They can run, but they cannot hide.”
Alexander’s posture straightens subtly, wincing as the movement aggravates his injuries. “Your orders?”
“Monitor, but do not engage. Let them think they’ve escaped.” I gesture toward the separated pack indicators. “Divided, they’re vulnerable. The alphas will be driven to recover their missing pieces.”
“And when they attempt to reunite?”
My smile carries neither warmth nor cruelty—only scientific certainty. “Then we collect our specimens. All of them.”
I tap the screen, bringing up schematics for the Aurora Facility—our most advanced research center, designed specifically for the next phase. “In the meantime, we proceed with global implementation. The designation revolution begins now.”
“Betas will either evolve or die,” Alexander states, repeating the mantra I’ve instilled since his youth.
“Not merely die,” I correct. “Transform. Those with suitable genetic potential will ascend to their true designation. Those without...” I shrug. “Nature has always favored the adaptable.”
“And Project Genesis?” Alexander inquires carefully. “How does it connect to the current formula deployment?”
My expression shifts to something almost paternal—the closest I come to genuine warmth. “Project Genesis goes beyond mere designation manipulation. It represents the next evolutionary leap—subjects who transcend traditional designation boundaries completely. The enhanced beta phenomenon we’re seeing in Cayenne is merely the first step.”
On a separate screen, profiles scroll past—candidates for the next phase of evolution. Children, mostly, their genetic profiles highlighted with Sterling markers.
“Nature made a fundamental error in designation distribution,” I state. “I’m simply correcting it. Creating a world where designation is determined not by random chance, but by deliberate design.”
“Your design,” Alexander observes.
“Our design,” I correct. “The Sterling legacy.”
“And what about Cayenne and Mona?” Alexander asks, unable to keep the personal interest from his voice. “Where do they fit into this legacy?”
I give my son a measured look. “They carry Sterling blood. Despite their rebellion, they represent the future. They’ll be given the opportunity to take their rightful place in the new order.”
“And if they refuse?”
“Everyone has leverage points,” I reply, pulling up footage of Pack Locke. “For Mona, it’s her scientific legacy. For Cayenne...”
My finger traces the image of the dispersed pack members—the feral alpha, the commanding leader, the vulnerable omega, the enhanced beta.
“Family,” I conclude with certainty. “Blood or chosen, it makes no difference. We’ll use one to secure the other.”
I close the surveillance feeds with a decisive gesture. “Update security protocols for all facilities. Implement the Aurora contingency—full mobilization of the facility for advanced subject containment. I want it ready for our new acquisitions within forty-eight hours.”
“Consider it done.” Alexander turns to leave, then hesitates. “Father... Cayenne. She’s different from what we expected.”
I study him closely, noting the conflict in his expression. “Different how?”
“Stronger. More... Sterling.” His admission seems to cost him something. “She reminds me of you.”
The comparison pleases me more than I let show. “All the more reason to bring her into the fold. Willingly or otherwise.”
As Alexander leaves, I return to the golden vial designed for Cayenne’s unique biology. My unexpected daughter—the variable I never planned for, yet might prove my greatest achievement.
Not the end of designation biology, but its evolution. My legacy, written not in history books, but in the genetic code of humanity itself.
“Welcome to the future,” I murmur to the empty laboratory. “Sterling designed.”